French Maritime Pine Bark: Standardization, Dosing, and Safety

Pine bark extract capsules beside raw bark
Pine bark extract capsules beside raw bark
Testing extract samples in the laboratory
Testing extract samples in the laboratory
Ground pine bark, the raw material
Ground pine bark, the raw material

The single fact that governs this whole topic is that the studied extract is one standardized product — not a generic herb. Nearly all of the research was done on this one extract, standardized to 65–75% procyanidins, which means the studies do not automatically apply to other “pine bark extract” products. This page covers what standardization means, what is actually in the extract, how it is absorbed, the doses used in trials, what is and is not known about its safety, the drug interactions that matter (blood thinners, blood-pressure and diabetes drugs, surgery), pregnancy considerations, and what systematic reviews say about the quality of the evidence.


Table of Contents

  1. One Standardized Extract, Not a Plant
  2. What “Standardized” Means
  3. The Evidence Is on This Extract
  4. What Is Actually In It
  5. Absorption and the Metabolite Story
  6. How Much, How Often, How Long
  7. Safety and Tolerability
  8. Drug Interactions and Surgery
  9. Pregnancy, Children, and Special Groups
  10. What the Systematic Reviews Say About the Evidence
  11. Products, Labels, and Testing
  12. Key Research Papers
  13. External Resources
  14. Connections
  15. Featured Videos

One Standardized Extract, Not a Plant

Most supplements are named for a plant or nutrient — “turmeric,” “magnesium,” “fish oil.” The studied pine bark extract is different: most trials used a single standardized, trademarked extract; results may not transfer to other pine bark products. It is one specific, patented extract of the bark of the French maritime pine, Pinus pinaster. The raw material, the extraction process, and the final composition are all controlled to a fixed specification.

This matters because products labeled “pine bark extract” are sold at a range of prices, and they are not necessarily the same thing: different pine species, different regions, different processing, and different procyanidin content. When a study reports that the extract “was shown to…,” the finding belongs to the standardized extract that was tested — and cannot simply be assumed for other pine bark products.

Back to Table of Contents

What “Standardized” Means

Plants are chemically variable. The same herb grown in two places, or harvested in two seasons, can differ several-fold in its active compounds. “Standardization” is the manufacturing practice of adjusting an extract so that every batch contains the same proportion of a chosen marker compound. The studied pine bark extract is standardized to 65–75% procyanidins (oligomeric proanthocyanidins, or OPCs).

Standardization is genuinely valuable: it is the reason researchers can compare studies and the reason the product is consistent from batch to batch. It also has limits. Standardizing to one class of marker does not guarantee that every minor component is identical, and it does not by itself prove effectiveness — it proves consistency. A consistent product that works is ideal; a consistent product still has to earn its clinical claims through trials, which brings us to the next point.

Back to Table of Contents

The Evidence Is on This Extract

Essentially all of the human research described across these Benefits pages — the venous, skin, and cardiovascular studies — used the same standardized pine bark extract. This is a real strength: unlike many herbs where studies used a hodgepodge of unstandardized preparations, here it is largely known what was tested. Rohdewald's (2002) review and Maimoona and colleagues' (2011) review both catalog this extract-specific body of work.

The flip side is a real gap in the evidence. Because the research is tied to one extract, the trial results have not been shown for generic “pine bark extract” products — a generic might be equivalent, weaker, or simply different in composition. The studied effects belong to the extract that was studied; other pine bark products may act as general-purpose antioxidants, but they are not backed by the same trials.

Back to Table of Contents

What Is Actually In It

The extract is a mixture, not a single molecule. Its main components are:

Packer and colleagues (1999) characterized the antioxidant chemistry of this procyanidin-rich mixture in detail. The practical takeaway is that the extract's effects probably come from the combination acting together, not from any one purified compound — which is another reason the specific standardized mixture, rather than an isolated ingredient, is what the science supports.

Back to Table of Contents

Absorption and the Metabolite Story

A fair question about any large polyphenol is whether the body actually absorbs it. Grimm and colleagues (2006) studied the pharmacokinetics of the standardized extract in healthy volunteers after single and repeated doses: 11 volunteers took a single 300 mg dose, and 5 took 200 mg daily for five days. Compounds from the extract were absorbed rapidly, most of them were still detectable over the whole 14-hour sampling period, and the study also traced ten previously unknown compounds in the blood. The picture that emerged is nuanced: the small constituents (such as ferulic acid, catechin, and taxifolin) are absorbed fairly directly, while the larger procyanidins are only partly absorbed intact and are substantially transformed by gut bacteria into smaller molecules.

One of these bacterial metabolites — a valerolactone often abbreviated M1 — appears in the blood after dosing and is thought to carry some of the biological activity, meaning part of what the extract does may actually be done by compounds the gut microbiome makes from it. Repeated dosing produced accumulation of active constituents, consistent with daily intake. Two implications follow: individual gut microbiomes may cause person-to-person variation in response, and in studies it was generally taken with food, which is reported to aid tolerability and give steadier exposure.

Back to Table of Contents

How Much, How Often, How Long

Across the clinical literature, the extract has been used at roughly 50 to 360 mg per day, with most trials clustering around 100–200 mg per day. Trials commonly split it into two or three doses (for example, 50 mg two or three times daily), taken with or after meals. Rough patterns by use, based on the studies:

Effects build over weeks, not days; most studies ran four to twelve weeks. There is no established benefit to megadosing, and no evidence that more is better above the studied range. These figures describe what researchers used, not a personal prescription.

A 2025 meta-analysis pooled 27 randomized trials with 1,685 participants. Compared with untreated groups, pine bark extract lowered systolic blood pressure by 2.26 mmHg, diastolic blood pressure by 2.62 mmHg, fasting blood sugar by 6.25 mg/dL, hemoglobin A1c (HbA1c) by 0.32%, body weight by 1.37 kg and LDL cholesterol by 5.07 mg/dL; it had no significant effect on HDL cholesterol, triglycerides, total cholesterol, insulin, body mass index, waist circumference or waist-to-hip ratio. The authors wrote that further high-quality trials with larger sample sizes and longer durations are required to validate these findings (Mohammadi et al., 2025).

Back to Table of Contents

Safety and Tolerability

Neither Cochrane review could judge the extract's safety. The 2012 review of 15 trials (791 participants) concluded that “no definitive conclusions regarding the efficacy or safety” of the extract are possible (Schoonees et al., 2012). The 2020 update of 27 trials (1,641 participants) found that, for most comparisons, studies did not report hospital admissions or serious adverse events, and reached the same conclusion on efficacy and safety (Robertson et al., 2020). The side effects reported for the extract are:

Two further limits apply. First, most safety data are short-term (weeks to a few months); long-term, everyday-use safety is less thoroughly documented. Second, trial results describe the average participant — individuals can still react, and supplements are not required to meet the safety-testing standards of medicines.

Back to Table of Contents

Drug Interactions and Surgery

The interactions reported in the literature all flow from the extract's own mild pharmacology:

Most of these are theoretical cautions rather than proven catastrophes, but the pattern — bleeding, blood pressure, blood sugar — is exactly where a “gentle” supplement can matter when stacked on real medication.

Back to Table of Contents

Pregnancy, Children, and Special Groups

Pregnancy and breastfeeding. A few studies used the extract in the second and third trimesters for venous problems and leg cramps without reported harm, but the overall safety data in pregnancy are limited, and there is little information for early pregnancy or breastfeeding. Because the pregnancy data are thin, it is not established as safe for use in pregnancy.

Children. The extract has been studied in children for specific conditions such as asthma (a randomized, placebo-controlled, double-blind study of 60 children and teenagers aged 6–18 with mild-to-moderate asthma; Lau et al., 2004) and attention deficit hyperactivity disorder (ADHD; one study with 61 participants in the 2020 Cochrane review); in those studies use was clinician-supervised, and there is little evidence on unsupervised pediatric use.

Other groups. The research raises a concern for people with autoimmune conditions (given the theoretical immune-stimulating effect), bleeding disorders, or those on multiple medications. As a general antioxidant supplement, the extract is not an established treatment for any diagnosed disease and has not been tested as a replacement for prescribed therapy.

Back to Table of Contents

What the Systematic Reviews Say About the Evidence

Systematic reviewers have weighed the quality of this research: the 2012 Cochrane review (Schoonees et al.) and the 2020 update on pine bark extract (Robertson et al.) both concluded that trials were generally small, heterogeneous, at risk of bias, and insufficient to draw firm conclusions for most conditions.

The 2020 Cochrane update covered 27 randomized trials (1,641 participants) in 10 chronic disorders. The overall risk of bias was low for four studies, high for one and unclear for 22, and for most comparisons the studies did not report hospital admissions or serious adverse events. The reviewers concluded that no definitive conclusions regarding the efficacy or safety of pine bark extract supplements are possible (Robertson et al., 2020).

This does not mean the results are fabricated or that the extract does nothing. It means the strength of the evidence is weaker than the volume of publications suggests, and that positive findings carry weight in proportion to their rigor. One example of the more rigorous kind is Enseleit and colleagues' (2012) randomized, double-blind, placebo-controlled cross-over trial in the European Heart Journal: 23 patients with coronary artery disease took 200 mg/day for 8 weeks, and placebo for 8 weeks, on top of standard cardiovascular therapy. Flow-mediated dilatation (how well the arm artery widens, a measure of blood-vessel lining function) improved from 5.3 to 7.0 with the extract, while no change was observed with placebo; inflammation markers, platelet adhesion and blood pressure did not change with either. More studies like that one are needed before any claim about the extract can be treated as settled.

Back to Table of Contents

Products, Labels, and Testing

A few facts about the products themselves and how the trials were run:

Back to Table of Contents

Key Research Papers

  1. Rohdewald P (2002). A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. International Journal of Clinical Pharmacology and Therapeutics — PubMed PMID: 11996210
  2. Maimoona A et al. (2011). A review on biological, nutraceutical and clinical aspects of French maritime pine bark extract. Journal of Ethnopharmacology — PubMed PMID: 21044675
  3. Grimm T et al. (2006). Single and multiple dose pharmacokinetics of maritime pine bark extract (Pycnogenol) after oral administration to healthy volunteers. BMC Clinical Pharmacology — PubMed PMID: 16887024
  4. Packer L, Rimbach G, Virgili F (1999). Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, Pycnogenol. Free Radical Biology and Medicine — PubMed PMID: 10490291
  5. Schoonees A et al. (2012). Pycnogenol (extract of French maritime pine bark) for the treatment of chronic disorders. Cochrane Database of Systematic Reviews — PubMed PMID: 22513958
  6. Robertson NU et al. (2020). Pine bark (Pinus spp.) extract for treating chronic disorders. Cochrane Database of Systematic Reviews — PubMed PMID: 32990945
  7. Enseleit F et al. (2012). Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. European Heart Journal — PubMed PMID: 22240497
  8. Belcaro G et al. (2008). Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. Redox Report — PubMed PMID: 19017467
  9. Lau BH et al. (2004). Pycnogenol as an adjunct in the management of childhood asthma. Journal of Asthma — PubMed PMID: 15641632
  10. Devaraj S et al. (2002). Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids — PubMed PMID: 12530550
  11. Stanislavov R et al. (2008). Improvement of erectile function with Prelox (Pycnogenol + L-arginine): a randomized, double-blind, placebo-controlled, crossover trial. International Journal of Impotence Research — PubMed PMID: 17703218
  12. Mohammadi S et al. (2025). Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis. BMC Complementary Medicine and Therapies — PubMed PMID: 39987124

PubMed Topic Searches

  1. PubMed: The standardised extract — pharmacology review
  2. PubMed: The standardised extract — pharmacokinetics / bioavailability
  3. PubMed: The standardised extract — safety / adverse effects
  4. PubMed: The standardised extract — procyanidin composition
  5. PubMed: Pine bark extract systematic reviews

Back to Table of Contents

External Resources

Back to Table of Contents

Connections

Back to Table of Contents